Q&A MMRERM

.

Feature	Measles	Mumps	Rubella (German Measles)	Fifth Disease (Erythema Infectiosum)	Roseola Infantum (“Sixth Disease”)	Mononucleosis
Causative Agent	Measles virus (paramyxovirus)	Mumps virus	Rubella virus	Human parvovirus B19	Human herpesvirus-6	Epstein-Barr virus (EBV) or cytomegalovirus (CMV)
Incubation Period	10 days (7-18 days for fever, 14 days for rash)	16-18 days (range 14-25 days)	14-21 days	4-20 days	10 days (range 5-15 days)	4-6 weeks
Contagious Period	5 days before to 4 days after rash appears	7 days before to 9 days after swelling onset	7 days before to 7 days after rash onset	7-10 days before rash onset	During high fever, before rash develops	Prolonged; most infectious at peak symptoms
Transmission	Airborne droplets	Direct/indirect contact with secretions	Contact with secretions	Respiratory secretions	Direct contact with secretions	Direct/indirect contact with secretions
Main Symptoms	Fever, cough, runny nose, conjunctivitis, rash, Koplik’s spots	Fever, headache, swollen salivary glands	Low-grade fever, malaise, rash	Flu-like symptoms, “slapped cheek” rash, lace-like body rash	High fever, rash, possible febrile seizures	Sore throat, swollen lymph nodes, fatigue, enlarged spleen/liver
Rash Characteristics	Maculopapular, erythematous, starts behind ears, spreads to body	No rash	Pinpoint rash starting on face, spreading downwards	”Slapped cheek” appearance, lace-like rash on body	Rosy-pink rash starting on neck/chest, spreads to body	Possible skin rashes
Complications	Pneumonia, otitis media, encephalitis, SSPE, diarrhea	Meningitis, orchitis, oophoritis, deafness, infertility	Congenital rubella syndrome (CRS) in infants	Severe anemia, hydrops fetalis in pregnancy, aplastic crisis	Febrile seizures, unknown long-term complications	Splenic rupture, jaundice, prolonged fatigue
Diagnosis	Clinical signs, measles IgM antibodies, virus RNA isolation	Clinical examination, saliva/blood test, PCR	Clinical signs, history of exposure	Clinical signs, history of exposure	Clinical signs, history of exposure	Monospot test, blood smear, symptoms
Treatment	Supportive care, vitamin A, MMR vaccine post-exposure	Supportive care, pain relief, avoid aspirin	Supportive care, exclude from school	Supportive care, exclude from school	Supportive care, exclude from school	Supportive care, avoid contact sports, hydration, vitamins
Prevention	MMR vaccine, exclude from school, immunoglobulin for high-risk contacts	MMR vaccine, exclude from school, dispose of contaminated articles	MMR vaccine, exclude from school	Good hygiene, exclude from school	Good hygiene, exclude from school	Good hygiene, avoid sharing items, exclude if symptomatic

Measles

1. Question: Describe the pathophysiology of measles and its clinical presentation.

   • Answer: Measles is caused by the measles virus, a paramyxovirus. It is highly contagious and spreads through respiratory droplets. The virus initially infects the respiratory tract, then spreads to the lymphatic system and bloodstream, leading to viremia. Clinically, measles presents with a prodrome of fever, cough, coryza, and conjunctivitis, followed by a maculopapular rash that starts on the face and spreads downward. Koplik’s spots, small white lesions on the buccal mucosa, are pathognomonic.

2. Question: Explain the complications associated with measles and the populations at greatest risk.

   • Answer: Complications of measles include diarrhea, otitis media, pneumonia, and encephalitis. Subacute sclerosing panencephalitis (SSPE) is a rare but fatal complication. Immunocompromised individuals, malnourished children, pregnant women, and those with vitamin A deficiency are at higher risk for severe complications.

3. Question: Discuss the strategies for measles prevention and control in a community setting.

   • Answer: Prevention strategies include vaccination with the MMR (measles, mumps, rubella) vaccine, which is highly effective. In outbreak settings, vaccination campaigns can be intensified, and post-exposure prophylaxis with the MMR vaccine or immunoglobulin can be administered. Isolation of infected individuals and public health education are also crucial.

4. Question: What are the diagnostic criteria for measles, and how is it confirmed in the laboratory?

   • Answer: Clinically, measles is diagnosed by the presence of fever, rash, and at least one of the three Cs: cough, coryza, or conjunctivitis. Laboratory confirmation involves detecting measles-specific IgM antibodies or isolating measles virus RNA from respiratory specimens. Salivary IgA testing can be used when blood samples are not feasible.

5. Question: Describe the treatment options for measles and the role of vitamin A supplementation.

   • Answer: There is no specific antiviral treatment for measles. Management is supportive, including hydration, antipyretics, and treatment of secondary bacterial infections. Vitamin A supplementation is recommended for children with measles, as it reduces the severity and mortality, particularly in those with vitamin A deficiency.

Mumps

6. Question: Outline the clinical features of mumps and its potential complications.

   • Answer: Mumps is characterized by fever, headache, and swelling of the parotid glands. Complications can include meningitis, orchitis in post-pubertal males, oophoritis in females, pancreatitis, and, rarely, deafness. Spontaneous abortion can occur in pregnant women during the first trimester.

7. Question: How is mumps transmitted, and what are the measures to prevent its spread?

   • Answer: Mumps is transmitted through respiratory droplets and direct contact with infected secretions. Prevention includes vaccination with the MMR vaccine. Infected individuals should be isolated, and good hygiene practices, such as handwashing and disinfecting contaminated surfaces, should be followed.

8. Question: Discuss the diagnostic approach to a suspected case of mumps.

   • Answer: Diagnosis is primarily clinical, based on the presence of parotitis. Laboratory confirmation can be done through PCR testing of saliva or blood for mumps virus RNA. Elevated serum amylase may indicate salivary gland involvement.

9. Question: What is the prognosis for mumps, and how does it differ between children and adults?

   • Answer: Mumps is generally self-limiting with a good prognosis. However, adults are more likely to experience complications such as orchitis and meningitis. Lifelong immunity usually follows infection, but reinfection can occur, typically with milder symptoms.

10. Question: Describe the management of mumps and the role of supportive care.

    • Answer: There is no specific antiviral treatment for mumps. Management is supportive, including analgesics for pain relief and applying ice or heat to swollen areas. Patients should avoid aspirin due to the risk of Reye’s syndrome.

Rubella

11. Question: Explain the clinical presentation of rubella and its significance in pregnant women.

    • Answer: Rubella presents with a low-grade fever, malaise, and a maculopapular rash that starts on the face and spreads downward. In pregnant women, rubella can cause congenital rubella syndrome (CRS) in the fetus, leading to hearing impairments, heart defects, and developmental delays.

12. Question: How is rubella transmitted, and what are the public health measures to control its spread?

    • Answer: Rubella is transmitted through respiratory droplets. Control measures include vaccination with the MMR vaccine and isolating infected individuals. Pregnant women should avoid contact with infected individuals to prevent CRS.

13. Question: Discuss the laboratory diagnosis of rubella.

    • Answer: Rubella is diagnosed by detecting rubella-specific IgM antibodies or viral RNA in clinical specimens. Serological testing can confirm immunity or recent infection.

14. Question: What are the prevention strategies for rubella, especially in the context of pregnancy?

    • Answer: Vaccination is the primary prevention strategy. Women of childbearing age should be vaccinated before pregnancy. During outbreaks, susceptible individuals should be identified and vaccinated.

15. Question: Describe the management of rubella and the importance of vaccination.

    • Answer: There is no specific treatment for rubella; management is supportive. Vaccination is crucial to prevent rubella and CRS. The MMR vaccine is safe and effective in providing immunity.

Fifth Disease (Erythema Infectiosum)

16. Question: Describe the clinical features of fifth disease and its typical progression.

    • Answer: Fifth disease, caused by parvovirus B19, presents with flu-like symptoms followed by a “slapped cheek” rash and a lacy rash on the body. The rash may reappear with exposure to sunlight or heat.

17. Question: What are the potential complications of fifth disease in specific populations?

    • Answer: In pregnant women, infection can lead to fetal hydrops and miscarriage. In individuals with hemolytic anemia, it can cause an aplastic crisis. Immunocompromised individuals may experience chronic anemia.

18. Question: How is fifth disease transmitted, and what are the preventive measures?

    • Answer: Fifth disease is transmitted through respiratory droplets. Preventive measures include good hygiene practices and avoiding contact with infected individuals, especially for pregnant women and those with chronic anemia.

19. Question: Discuss the diagnostic approach for fifth disease.

    • Answer: Diagnosis is primarily clinical based on the characteristic rash. Serological testing for parvovirus B19-specific IgM antibodies can confirm recent infection.

20. Question: What is the management of fifth disease, and how does it differ in high-risk groups?

    • Answer: Management is supportive, focusing on symptom relief. High-risk groups, such as pregnant women and individuals with chronic anemia, may require additional monitoring and intervention.

Roseola Infantum

21. Question: Explain the clinical presentation and typical age group affected by roseola infantum.

    • Answer: Roseola infantum, caused by human herpesvirus-6, typically affects children aged 6 months to 2 years. It presents with a high fever followed by a rosy-pink rash as the fever resolves.

22. Question: How is roseola transmitted, and what are the preventive measures?

    • Answer: Roseola is transmitted through direct contact with respiratory secretions. Preventive measures include good hygiene practices and avoiding contact with infected individuals.

23. Question: Discuss the complications associated with roseola and the populations at risk.

    • Answer: Complications are rare but can include febrile seizures. Immunocompromised individuals may experience more severe disease.

24. Question: How is roseola diagnosed, and what are the key clinical features?

    • Answer: Diagnosis is clinical, based on the sudden onset of high fever followed by a rash. Laboratory testing is rarely needed.

25. Question: Describe the management of roseola and the role of supportive care.

    • Answer: Management is supportive, including antipyretics for fever and ensuring adequate hydration. Most children recover without complications.

Mononucleosis

26. Question: Describe the etiology and clinical presentation of mononucleosis.

    • Answer: Mononucleosis is primarily caused by the Epstein-Barr virus (EBV). It presents with fever, sore throat, lymphadenopathy, fatigue, and splenomegaly.

27. Question: How is mononucleosis transmitted, and what are the preventive measures?

    • Answer: Mononucleosis is transmitted through saliva, often referred to as the “kissing disease.” Preventive measures include avoiding sharing utensils and close contact with infected individuals.

28. Question: Discuss the diagnostic approach for mononucleosis.

    • Answer: Diagnosis is based on clinical symptoms and confirmed with the Monospot test or EBV-specific serology. Blood tests may show atypical lymphocytes and elevated white blood cell count.

29. Question: What are the potential complications of mononucleosis, and how are they managed?

    • Answer: Complications include splenic rupture, hepatitis, and secondary bacterial infections. Management is supportive, with rest and avoidance of contact sports to prevent splenic rupture.

30. Question: Describe the treatment and prognosis of mononucleosis.

    • Answer: There is no specific antiviral treatment for mononucleosis. Management includes rest, hydration, and analgesics for symptom relief. Most individuals recover fully, but fatigue may persist for weeks to months.